Dr. Mohamad F. Jamiluddin, a former fellow in the Division of Hematology and Medical Oncology, obtained a patent and produced several research papers in the field of HIV-AIDS within his first two years of training. His journey – emigrating from India to America – is featured in a documentary premiering on HBO, July 4, 2011.
Anne Moore, M.D., Professor of Clinical Medicine and Medical Director of the Weill Cornell Breast Center, will be honored by The New York Academy of Medicine with the 2011 Academy Plaque for Exceptional Service to the Academy. Dr. Moore specializes in the research and treatment of breast cancer.
Acute myelogenous leukemia (AML), with more than 12,000 new diagnoses each year, is a particularly stealthy cancer. But a team of researchers led by Ari M. Melnick, M.D., Associate Professor of Medicine at Weill Cornell Medical College, have caught it in the act.
Research from the laboratory of Ari M. Melnick, M.D. has resulted in a promising new combinatorial therapy for diffuse large B cell lymphoma, an aggressive and rapidly progressive cancer that affects approximately 21,000 new people each year. This research, published in The Journal of Clinical Investigation, may hold significant implications for patient survival rates.
Monica L. Guzman, Ph.D., Assistant Professor of Pharmacology in Medicine, Weill Cornell Medical College, is among this year's recipients of the National Institutes of Health Director's New Innovator Awards. Established in 2008 to stimulate highly innovative research and support promising new investigators, the five-year award is for $1.5 million.
This award is presented annually to members of the Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research. The award has been generously supported by the Michael Wolk Foundation.
The Fellows Research Award is presented annually to fellows within the Department of Medicine who have presented outstanding research.
Researchers from the Sackler Center at WCMC have designed a new class of drugs that targets a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma. Findings published April 14 in Cancer Cell show that an experimental compound designed by the researchers may effectively block the cancer-causing actions of the protein known as BCL6 by attaching to a critical "hot spot" on its surface, thus killing the cancer cells.
Leading hematologists in the Department of Medicine presented new basic and clinical research findings at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Dec. 5-8.
Dr. Guzman is widely regarded as a pioneer and expert in devising therapies that target leukemia stem cells. Her research has pioneered the new field of cancer stem cell targeted therapy. To complement her basic laboratory research, she will closely collaborate with our clinical faculty on novel therapies to target leukemia stem cells.
